Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy
This study is evaluating whether acupuncture may help reduce hot flashes in men receiving hormone therapy for prostate cancer. Hot flashes are a common side effect of androgen deprivation therapy (ADT) and may negatively affect sleep, mood, concentration, daily activities, and overall quality of life.
Participants enrolled in this study will receive acupuncture treatment over a defined treatment period. The study will assess changes in hot flash frequency, severity, and quality of life using patient questionnaires and symptom diaries. Participants will complete a daily hot flash diary during selected 7-day assessment periods and quality-of-life questionnaires during study visits.
The primary goal of this study is to determine whether acupuncture may improve hot flash symptoms and related quality of life in men undergoing treatment for prostate cancer.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Hot flashes are a common and bothersome side effect experienced by men receiving androgen deprivation therapy (ADT) for prostate cancer. Symptoms may include sudden warmth, sweating, flushing, sleep disturbance, fatigue, mood changes, and reduced quality of life. Although medications such as antidepressants may help some patients, these treatments may also cause side effects and are not effective for all individuals. Acupuncture has been studied as a non-drug approach for management of hot flashes, but additional prospective studies are needed in men with prostate cancer receiving ADT.
This study is a prospective clinical study evaluating acupuncture for the management of ADT-related hot flashes in men with prostate cancer. Participants will undergo acupuncture treatment during the active treatment phase according to the study treatment schedule.
The study will evaluate changes in:
Hot flash frequency Hot flash severity Hot flash-related quality of life Interference of hot flashes with daily activities, sleep, mood, and social functioning
Patient-reported outcomes will be collected using standardized symptom assessments, including:
A Hot Flash Daily Diary The Hot Flash Related Daily Interference Scale (HFRDIS)
Participants will complete a daily hot flash diary during predefined 7-day assessment windows at baseline, during treatment, at the end of treatment, and during follow-up. The diary records the number and severity of hot flashes experienced over a 24-hour period. Participants will also complete questionnaires evaluating how hot flashes affect daily activities and quality of life.
The study includes follow-up assessments after completion of acupuncture treatment to evaluate the durability of symptom improvement over time.
The primary objective of the study is to assess whether acupuncture reduces hot flash burden in men receiving ADT for prostate cancer. Secondary objectives include evaluation of quality-of-life outcomes, symptom trajectory over time, treatment feasibility, and patient adherence to acupuncture-based symptom management.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Zin Myint, MD
- Telefoonnummer: 850-323-3964
- E-mail: zwmy222@uky.edu
Studie Contact Back-up
- Naam: Maria Hoover, BS
- Telefoonnummer: 859-323-3065
- E-mail: Maria.Hoover@uky.edu
Studie Locaties
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40536
- Werving
- University of Kentucky
-
Contact:
- Zin Myint, MD
- E-mail: zin.myint@uky.edu
-
Hoofdonderzoeker:
- Zin Myint, MD
-
Onderonderzoeker:
- Courtney Lantz, Dipl. Ac., L. Ac
-
Contact:
- Maria Hoover, BS
- Telefoonnummer: 859-323-3065
- E-mail: Maria.Hoover@uky.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Patients with history of prostate cancer with currently receiving hormone therapy or had received hormone therapy in the past two years
- Hormone therapies may include androgen deprivation therapy ( ADT; e.g., leuprolide, degarelix, or relugolix) or androgen signaling inhibitors (e.g., enzalutamide, apalutamide, or darolutamide) or adrenal steroid synthesis inhibitor (e.g., abiraterone acetate).
- Patients may also receive additional treatments such as chemotherapy, radioligand therapy or target therapy in combination with hormone therapy.
- Reports hot flashes at least twice per day. Patients may already be taking medications for hot flashes. There is no limit on the number of hot flash medications they can be using.
- ECOG performance status =3 (see Appendix A).
- Patients may participate in other therapeutic clinical trials for the treatment of prostate cancer. They will remain eligible as long as they meet the eligible criteria.
- Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.
- Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.
- Patients with a prior or concurrent malignancy are eligible for this trial.
- Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.
Exclusion Criteria:
- Patients can't travel for acupuncture
- Patients with high bleeding tendency as determined by PI
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Real Acupuncture
Participants receive acupuncture administered by a licensed and NCCAOM board certified acupuncturist at predefined acupuncture points twice weekly for 6 weeks followed by a 4 week washout period before participants crossover to the sham acupuncture arm.
|
The Real Acupuncture is administered at bilateral Large Intestine 4, Kidney 7, Kidney 3, and Gall Bladder 39 points using sterile single-use filiform needles.
Needles are inserted approximately 20-25 mm with manipulation to achieve de qi sensation and retained for 30 minutes.
Treatments are administered twice weekly for 6 weeks.
|
|
Actieve vergelijker: Sham Acupuncture
Participants receive acupuncture administered by a licensed and NCCAOM board certified acupuncturist at non-acupuncture points twice weekly for 6 weeks followed by a 4 week washout period before participants crossover to the real acupuncture arm.
|
The Sham Acupuncture administered at non-acupuncture points bilaterally using sterile single-use filiform needles.
Needles are inserted approximately 4-5 mm without manipulation.
Needles are retained for 30 minutes.
Treatments are administered twice weekly for 6 weeks.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Hot Flash Score
Tijdsspanne: Baseline and week 6
|
Weekly hot flash score will be calculated from a 7-day hot flash diary.
Daily hot flash score is calculated as the number of hot flashes per day multiplied by the maximum severity score for that day.
Weekly hot flash score is calculated as the sum of daily hot flash scores over 7 days.
The primary outcome is the change in weekly hot flash score from baseline to Week 6.
|
Baseline and week 6
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Hot Flash Related Daily Interference Scale (HFRDIS) Score
Tijdsspanne: Baseline, Week 6, Week 16
|
Change in Hot Flash Related Daily Interference Scale (HFRDIS) total score from baseline.
The HFRDIS is a validated 10-item patient-reported questionnaire assessing the impact of hot flashes on daily functioning and quality of life.
Each item is scored from 0 to 10, with higher scores indicating greater interference from hot flashes.
|
Baseline, Week 6, Week 16
|
|
Proportion of Participants Achieving ≥50% Reduction in Weekly Hot Flash Score
Tijdsspanne: Week 6 and Week 16
|
Proportion of participants achieving at least a 50% reduction in weekly hot flash score compared with baseline, based on 7-day hot flash diary assessments.
|
Week 6 and Week 16
|
|
Change in Mean Daily Hot Flash Frequency
Tijdsspanne: Baseline, Week 6, Week 16
|
Change in the mean number of daily hot flashes recorded in the 7-day hot flash diary compared with baseline.
|
Baseline, Week 6, Week 16
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 111460
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .